Chronic Lymphocytic Leukemia

Diagnose CLL when peripheral blood contains at least 5 × 10⁹/L clonal B lymphocytes for at least 3 months with a characteristic CLL immunophenotype. Flow cytometry should demonstrate the characteristic B-cell phenotype, including CD19, CD5, CD20, CD23, and light-chain restriction. BMJ+1BMJChronic lymphocytic leukaemia - Symptoms, diagnosis and treatment | BMJ Best PracticePubMedGuidelines for the diagnosis and treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma from Chronic Lymphocytic Leukemia Spanish Group (GELLC) - PubMed

Below this blood clonal-B-cell threshold, classify a CLL-phenotype clone as monoclonal B-cell lymphocytosis (MBL) when there is no disease-defining marrow-infiltration cytopenia. CLL and small lymphocytic lymphoma are the same disease with different anatomic presentations and are treated similarly. PubMed+1PubMedGuidelines for the diagnosis and treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma from Chronic Lymphocytic Leukemia Spanish Group (GELLC) - PubMedPubMedDiagnosis and treatment of chronic lymphocytic leukemia: 2025 recommendations of the Brazilian Group of Chronic Lymphocytic Leukemia of the Brazilian Association of Hematology and Hemotherapy (ABHH)

Obtain a CBC with differential, peripheral smear, and peripheral-blood flow cytometry for suspected CLL. Routine bone marrow biopsy and routine cross-sectional or PET imaging are not required for initial diagnosis; consider marrow evaluation when cytopenias are unexplained or diagnostic uncertainty persists. BMJ+1BMJChronic lymphocytic leukaemia - Symptoms, diagnosis and treatment | BMJ Best PracticePubMedDiagnosis and treatment of chronic lymphocytic leukemia: 2025 recommendations of the Brazilian Group of Chronic Lymphocytic Leukemia of the Brazilian Association of Hematology and Hemotherapy (ABHH)

Stage clinically using Rai or Binet systems; iwCLL integrates Rai and Binet categories for standardized disease assessment. PubMedPubMedChronic Lymphocytic Leukemia Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf Early-stage disease often follows a slow course, and some untreated patients have survival similar to the general population. BMJ+1BMJChronic lymphocytic leukaemia - Symptoms, diagnosis and treatment | BMJ Best PracticePubMedChronic Lymphocytic Leukemia - StatPearls - NCBI Bookshelf

Before initiating therapy, test for del(17p) by FISH and TP53 mutation by DNA sequencing. iwCLL-based recommendations support this testing because TP53-disrupted CLL has a high likelihood of poor response or early relapse after chemoimmunotherapy. PubMed+1PubMedTreatment of Chronic Lymphocytic Leukemia in the Personalized Medicine EraPubMedChronic Lymphocytic Leukemia - StatPearls - NCBI Bookshelf FISH using four probes and assessment of immunoglobulin heavy-chain variable-region mutation status are also recommended in contemporary guideline-based prognostic evaluation. PubMedPubMedGuidelines for the diagnosis and treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma from Chronic Lymphocytic Leukemia Spanish Group (GELLC) - PubMed

Reassess predictive genetics before subsequent lines of therapy rather than assuming results remain clinically sufficient from the initial workup; treatment selection in relapsed disease depends on prior treatment class, reason for discontinuation, patient factors, and available trials. PubMed+1PubMedClinical practice guidelines for the diagnosis and management of chronic lymphocytic leukemia in Saudi Arabia: consensus statement by an expert panelPubMedChronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy

Active surveillance is appropriate for asymptomatic Rai 0-II or Binet A-B disease until symptoms or other accepted indications for treatment emerge. BMJBMJChronic lymphocytic leukemia - Management Approach | BMJ Best Practice US Randomized comparisons of immediate versus delayed treatment did not show a significant long-term survival benefit from early treatment initiation in otherwise asymptomatic patients. PubMedPubMedChronic Lymphocytic Leukemia - StatPearls - NCBI Bookshelf

At surveillance visits, reassess symptoms, lymphadenopathy and splenomegaly, CBC trends, and evolving cytopenias. The relevant transition is from clinically stable disease to iwCLL-defined active disease, including clinically symptomatic disease. PubMed+1PubMedChronic Lymphocytic Leukemia - StatPearls - NCBI BookshelfASCOWhen and How Long to Treat Chronic Lymphocytic Leukemia? The supplied evidence does not provide sufficiently detailed iwCLL thresholds for cytopenias, lymphocyte kinetics, nodal bulk, or constitutional symptoms; verify current iwCLL or NCCN criteria when making a treatment-start decision. BMJ+2BMJChronic lymphocytic leukemia - Management Approach | BMJ Best Practice USScienceDirectiwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLLASCOWhen and How Long to Treat Chronic Lymphocytic Leukemia?

BTK inhibitors and BCL2 inhibitors have replaced chemoimmunotherapy for most patients in first- and second-line CLL. PubMedPubMedChronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy Anti-CD20 monoclonal antibodies may be incorporated into targeted regimens, while chemoimmunotherapy is now reserved for selected circumstances based on molecular profile, age, and fitness. BMJ+1BMJChronic lymphocytic leukemia - Management Approach | BMJ Best Practice USPubMedChronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy

Continuous BTK inhibitor therapy provides ongoing disease control but generally leaves measurable residual disease detectable, and patients may ultimately discontinue because of adverse effects or relapse. Fixed-duration combination regimens can achieve undetectable measurable residual disease, although recurrence still occurs in a meaningful proportion of patients. PubMedPubMedChronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy These differing treatment-duration and response-depth goals should be discussed explicitly.

The supplied sources identify the major treatment classes and broad tradeoffs but do not provide FDA-label-supported dosing, titration, renal or hepatic adjustments, contraindications, interaction management, or comparative selection among individual BTK inhibitors. Use current U.S. prescribing information and an up-to-date CLL pathway before prescribing a specific regimen.

After prior BTK inhibitor therapy, switching to a BCL2 inhibitor strategy, or vice versa, is a current standard approach. PubMedPubMedChronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy In relapsed or refractory disease, selection should account for prior therapies, whether treatment ended because of resistance versus intolerance, comorbidities, concomitant medications, treatment goals, and clinical-trial access. PubMedPubMedClinical practice guidelines for the diagnosis and management of chronic lymphocytic leukemia in Saudi Arabia: consensus statement by an expert panel

There are no head-to-head trials directly comparing BTK and BCL2 inhibitors in relapsed or refractory CLL in the supplied evidence base; therefore, class sequencing remains individualized rather than algorithmically settled. PubMedPubMedClinical practice guidelines for the diagnosis and management of chronic lymphocytic leukemia in Saudi Arabia: consensus statement by an expert panel Patients refractory to both BTK and BCL2 inhibitor classes have no established standard therapy and should be considered for clinical trials or referral to a CLL-focused center. PubMedPubMedChronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy

Allogeneic hematopoietic stem-cell transplantation is generally reserved for younger, fit, high-risk patients who have failed a pathway inhibitor and should prompt early transplant-center assessment when applicable; it is generally unsuitable for older patients when alternatives exist because of mortality risk. PubMedPubMedClinical practice guidelines for the diagnosis and management of chronic lymphocytic leukemia in Saudi Arabia: consensus statement by an expert panel

During observation, monitor for evolving symptoms, organ enlargement, and CBC changes that may signal active disease. BMJ+1BMJChronic lymphocytic leukemia - Management Approach | BMJ Best Practice USPubMedChronic Lymphocytic Leukemia - StatPearls - NCBI Bookshelf During targeted therapy, monitor according to the selected drug's toxicity profile and label-directed laboratory requirements; targeted therapies have distinct adverse-effect profiles, and tumor lysis syndrome has been reported in treated CLL. BMJBMJChronic lymphocytic leukemia - Treatment algorithm

Do not use measurable residual disease as a stand-alone reason to alter routine care outside a regimen-specific or trial-defined context based on the supplied evidence. Contemporary guidelines address measurable residual disease in clinical evaluation, and fixed-duration combinations may achieve undetectable measurable residual disease, but recurrence remains possible. ScienceDirect+1ScienceDirectiwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLLPubMedChronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy